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Current therapies for advanced hepatocellular carcinoma
(HCC) are marginally effective and exacerbate underlying
liver disease. The ability of immunotherapy to elicit nontoxic,
systemic, long-lived anti-tumor activity makes it particularly
well-suited for use in the setting of HCC. While therapeutic
benefit has been achieved in early clinical trials, the efficacy of
immune-based therapies is limited by several unique
properties of HCC, most notably the inherently tolerogenic
character of the liver in both healthy and diseased (chronically-
infected or tumor-bearing) states. Therapeutic regimens that
both counteract these immunosuppressive mechanisms and
amplify tumor-specific immunity are expected to profoundly
improve clinical outcomes for HCC patients.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers in the world, with a global incidence of over 600,000
new cases per year. While the majority of cases are primarily in
sub-Saharan Africa and Eastern Asia, it is also the fastest growing
cause of cancer-related death of US males.
1 Within the past 30 y,
the incidence and mortality rates for hepatocellular carcinoma
(HCC) have tripled in the United States.
2 Racial differences in
HCC incidence have been observed in the US, where Asians have
higher rates than African Americans, who have higher rates than
Caucasians.
2 The primary risk factors for developing HCC are
cirrhosis (independent of its etiology), and chronic infection with
hepatitis B virus (HBV) or hepatitis C virus (HCV). In the
United States, it is estimated that chronic HCV infection is
attributed to 47% of HCC cases, with an additional 15%
associated with HBV.
3 HBV infection is endemic in South-East
Asia and Sub-Saharan Africa, and there is a global pandemic of
hepatitis C virus (HCV) infection. HCV infection, which
increases the risk of developing HCC by approximately 17-fold,
likely accounts for the increased incidence of HCC observed in
several Western countries, where incidence has risen to 5–20/
100,000 in Spain, Italy and Greece, and to 1–3.6/100,000 in the
UK, Canada and the United States.
1 As diabetes, obesity and
metabolic syndrome are also hypothesized risk factors, HCC is
expected to become a progressively greater health problem in the
near future.
4
Current therapies. Once diagnosed, HCC has a dismal pro-
gnosis. Small, localized tumors are potentially curable with sur-
gery (resection and liver transplantation). Unfortunately, less
than 20% of HCC patients are eligible for these procedures
because most patients have advanced disease at diagnosis, have
liver dysfunction limiting aggressive treatment, or have recurrent
disease.
5 Local regional therapy is largely palliative and includes
cryoablation, radiofrequency ablation (RFA), and transarterial
embolization (TAE), in which obstruction of the hepatic artery
induces subsequent tumor necrosis. HCC is notoriously resistant
to chemotherapy and other systemic treatment modalities. The
multi-targeted kinase inhibitor sorafenib, which improves survival
by 2.3–2.8 mo, is the only systemic agent found to increase
survival time in patients with advanced HCC and is currently
the standard of care for these patients.
6,7 Overall however, the
median survival for patients with advanced stage, unresectable
HCC is less than 1 y.
5
These reports underline the need for novel therapies for
patients with this disease. A number of other molecularly targeted
approaches, all of which target signaling pathways activated in
HCC, are under investigation. These agents include bevacizumab,
a vascular endothelial growth factor (VEGF) neutralizing anti-
body, sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI),
and erlotinib, an EGFR inhibitor.
7 However, the drug-metabolizing
properties of the liver, in addition to elevated levels of multidrug
resistance proteins expressed by HCC cells, likely contributes to
the limited efficacy of chemotherapeutics and small molecule drugs
in the treatment of HCC.
8 Moreover, these agents typically have
intrinsic hepatotoxicity that may further compromise liver function.
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Immunotherapy represents an attractive alternative to these
traditional therapies based on the sensitivity, specificity, and self-
renewing capacity of the immune system.
Immunosuppressive Factors in HCC
Perhaps the most formidable barrier to immune-based therapy
of HCC is the unique immunobiology of the liver. As described
below, a plethora of regulatory mechanisms sustain the immuno-
suppressive milieu of the liver in both healthy and diseased
(chronically-infected or tumor-bearing) states.
Inherent tolerogenicity of the liver. Blood from the arterial
circulation and the intestines enter the liver, where toxins and
gut-derived microbial products are captured and eliminated. To
prevent aberrant immunity in response to continual pathogen
exposure, the liver has evolved a unique and redundant system
of immune regulation, as demonstrated by relatively low rates of
liver allograft rejection and limited need for immune suppression
post-transplant. Hepatocytes contribute to the liver’s inherent
tolerogenicity by priming naïve T cells in the absence of costimu-
lation, resulting in defective cytotoxicity and clonal deletion.
9,10
Alternatively, naïve T cells that initially encounter antigen in the
lymph nodes acquire full effector function, suggesting that
effective immunotherapy in the setting of HCC must aim to
avoid intrahepatic T cell priming.
Three distinct subsets of phagocytic cells in the liver clear
foreign material from the blood and serve as tolerogenic antigen
presenting cells (APC): (1) liver sinusoidal endothelial cells
(LSEC), (2) Kupffer cells and (3) liver dendritic cells (DC). Liver
sinusoidal endothelial cells line the hepatic vasculature and
transport proteins from the circulation into the liver parenchyma.
The specialized scavenger properties of LSEC also allows for
the uptake, processing, and presentation of exogenous antigens
on both major histocompatibility complex (MHC) class I and
class II molecules. Cross-presentation of systemic antigen by
these cells has been shown to induce antigen-specific CD8+
T cell tolerance through interactions between the inhibitory
molecule B7-H1/PD-L1 expressed by LSEC and PD-1 on the
T cells.
10 Importantly, high levels of exogenous interleukin-2
(IL-2) are capable of attenuating LSEC-mediated CD8+ T cell
tolerance and restoring full T effector cell function.
11 While high
dose IL-2 has been approved for use in melanoma and renal cell
carcinoma, limitations of this therapy include severe side effects
and expansion of Foxp3+ regulatory T cells (Treg).
12
Kupffer cells are tissue-resident macrophages that contribute
to the immunosuppressive milieu of the liver through produc-
tion of the anti-inflammatory molecules transforming growth
factor-b (TGF-b), IL-10 and prostaglandin E2 (PGE2).
10 Kupffer
cells also support systemic tolerance by eliminating high affinity
antigen-specific CD8+ T cells that enter the liver.
13 Liver-resident
DC represent another major subset of tolerogenic APC in the
liver microenvironment. Priming of naïve CD4+ T cells by IL-10-
secreting liver DC results in Th2 polarization, Treg induction,
and poor antigen recall responses.
10 Additionally, myeloid DC
precursors that enter the liver differentiate into IL-10-producing
regulatory DC, indicating that in order to generate robust
anti-HCC immunity, extrahepatic DC differentiation and
maturation will be necessary.
14
Chronic HBV- and HCV-mediated immunosuppression.
While persistent HBV or HCV infection can contribute to the
development of HCC by driving chronic liver inflammation, the
many immunosuppressive properties of chronic HBV or HCV
infection have also been well-documented. For example, co-
culture of the hepatitis B core antigen (HBcAg) with peripheral
blood mononuclear cells (PBMC) from patients with chronic
HBV infection induced elevated IL-10 production vs. PBMC
from healthy controls.
15 Dysfunctional T cell responses to both
virus-specific and unrelated antigens, characterized by impaired
proliferation and IL-2 production, are also observed in chronic
HBV-infected patients.
16 Furthermore, the frequencies of intra-
hepatic Treg in these patients correlates with viral load, suggest-
ing that Treg accumulation in the chronically-infected liver
may abrogate CD8+ T cell-mediated clearance of these viruses.
17
Chronic HCV infection has been found to negatively regulate
both innate and adaptive arms of the immune system.
18
Monocyte-derived DC from HCV-infected patients, but not
from healthy control donors, maintain an immature phenotype in
response to maturation stimuli.
19 Because monocyte-derived DC
from healthy donors cultured in the presence of HCV polyprotein
also fail to respond to maturation stimuli, this inhibitory effect
appears to be mediated through viral proteins.
20 Natural killer
(NK) cells, which are abundant in the liver, are also susceptible
to the tolerogenic properties of HCV-derived proteins. For
example, high concentrations of HCV envelope protein E2
inhibit the effector function (IFN-c production and cytotoxicity)
of NK cells isolated from healthy donors.
21 At the T cell level,
upregulation of the inhibitory receptors PD-1 and Tim-3, which
correlates with T effector cell dysfunction, has been observed on
both HCV-specific and HCV-nonspecific CD8+ T cells in the
circulation and livers of patients with chronic HCV infection vs.
normal controls.
22,23 Partial restoration of T cell proliferation and
IFN-c secretion was achieved ex vivo by inhibiting the binding
of PD-1 and Tim-3 to their respective ligands (B7-H1 and
Gal-9). Importantly, a recent report has demonstrated that
prolonged administration of IFN-a, a standard therapy for
persistent HCV infection, promoted telomere loss in naïve T
cells.
24 Given the correlation between shortened T cell telomeres
and terminal differentiation (characterized by diminished prolif-
erative potential), IFN-a-induced T cell “exhaustion” likely
represents a significant barrier for immunotherapy in HCV-
infected patients.
25
Mechanisms of HCC immune escape. In response to the
accumulating literature supporting the ability of tumors to sub-
vert an immune attack, Hanahan and Weinberg have recently
updated their “Hallmarks of Cancer” to include tumor immune
evasion.
26 HCC is not unlike cancers of other etiologies in that
numerous regulatory mechanisms involving nearly all cellular
subsets of the immune system contribute to tumor development
and progression. Compared with healthy controls, the peripheral
blood of HCC patients contain reduced frequencies of myeloid
DC, which exhibit impaired IL-12 production and limited allo-
stimulatory activity.
27 Diminished NK cell frequencies and
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functional impairment has also been described in HCC patients.
28
Moreover, NK cell dysfunction in these patients may be attri-
butable to an expanded population of myeloid-derived suppressor
cells (MDSC), which have been recently shown to inhibit NK cell
activity through a cell contact-dependent mechanism.
29
A type-1 polarized tumor-specific T cell response is an essential
component of robust anti-tumor immunity. Budhu and collea-
gues have demonstrated that liver-infiltrating lymphocytes in
HCC patients exhibit a type-2-skewed anti-inflammatory profile
that correlates with metastatic potential.
30 As in both the healthy
liver and chronically HBV/HCV-infected liver, PD-1-B7-H1
interactions play an important role in maintaining immune
tolerance in the setting of HCC. In individuals with persistent
HBV infection, PD-1 expression by peripheral blood CD8+
cytotoxic T lymphocytes (CTL) is upregulated with disease
progression from cirrhosis to HCC.
31 Aberrantly-activated
monocytes that are enriched in HCC lesions have been shown
to express high levels of the PD-1 ligand B7-H1 through a
mechanism involving autocrine TNF-a and IL-10 production.
32
Notably, B7-H1 neutralization enhanced human PD-1+CD8+
T cell survival in vitro and restored tumor-specific T cell
immunity in a tumor xenograft model.
31 Finally, the induction,
expansion, and/or recruitment of Treg in the HCC tumor
microenvironment are indisputable barriers to robust anti-tumor
immunity, as intratumoral Treg density is associated with poor
clinical prognosis.
31 Maintenance of an expanded pool of Treg in
HCC patients is accomplished in part by MDSC, which have
been shown to promote the conversion of naïve CD4+ T cells
from the peripheral blood of these patients into Foxp3+ Treg.
33
In summary, the liver is comprised of a dynamic network of
specialized cell subsets that maintain immune privilege through
redundant regulatory mechanisms. Three distinct liver micro-
environments, varying with disease state and all polarized toward
negative immune regulation, have been characterized (Fig.1).
These numerous tolerogenic factors may accumulate during
HBV/HCV-mediated hepatocarcinogenesis and coincide in
advanced HCC lesions, facilitating an aggressive and effective
counterattack to anti-HCC immunity. Future studies will be
needed to address this notion.
Immunotherapy of HCC
While HCC is not generally considered an “immunogenic”
tumor, patients whose tumors contain lymphocytic infiltrates
show longer survival and lower risk of recurrence.
34 In the past
15 y, several tumor-associated antigens for HCC have been
identified, and a measure of success has been achieved in early
clinical trials.
HCC-specific antigens. AFP is an oncofetal antigen and is
the most abundant serum protein in the fetus.
35 At birth, levels
drop to 30–100 mg/ml and the adult level of AFP is 1–3 ng/ml.
It is produced at high levels by the visceral endoderm of the
yolk sac and fetal liver, and is transcriptionally repressed shortly
after birth. Forty to 80% of HCC and germ cell tumors express
Figure1. Evolving liver immunobiology during HCC development. Numerous tolerogenic factors, many of which are listed here, support
immunoregulation in both the steady-state and diseased (chronically-infected or tumor-bearing) liver. These immunosuppressive mechanisms likely
accumulate during HBV/HCV-mediated hepatocarcinogenesis and coexist in patients with advanced HCC lesions. See text for all associated references.
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AFP, and serum assays play an important role in diagnosis and
monitoring responses to treatment; levels . 20 ng/ml are
generally considered abnormal, and . 200 ng/ml are specific for
HCC in patients with cirrhosis.
5 Human AFP is translated as
a 609 residue polypeptide that is cleaved to yield a 590 amino
acid secreted protein. The function of AFP is unknown. It has
been hypothesized to play a role in the transport of serum
components, including fatty acids, steroids, and heavy metals.
36
There have also been reports of an immunoregulatory role of
AFP.
37
Although high levels of soluble AFP present during deve-
lopment could have a broad impact on the developing T cell
repertoire, including deletion of high affinity T cells, murine
studies have demonstrated that murine AFP can serve as a tumor
rejection antigen.
38 Studies in HCC patients indicate that
circulating AFP-specific T cells can be activated ex vivo and can
recognize tumor despite high circulating serum levels of this
antigen.
39-41 Polyclonal AFP-specific T cells can also be detected
in the livers of chronically infected HCV patients and HCC
patients.
42 Furthermore, elimination of Treg can unmask AFP-
specific T cells in HCC patients.
43 Importantly, AFP expression
in HCC is associated with increased tumor proliferation, apopto-
sis resistance, and it is expressed in CD45-CD90+ HCC cancer
stem cells, supporting its targeting as a biologically relevant
tumor associated antigen.
36,44
Among additional tumor antigens implicated in anti-HCC
immunity are the cancer-testes antigens, such as those of the
highly homologous MAGE-A family, which have demonstrated
considerable immunogenicity in several clinical trials. MAGE-A3,
for example, has been found to be overexpressed in 24–70%
of HCC.
45 Glypican-3 (GPC3), a cell surface heparin sulfate
proteoglycan, is expressed by 84% of HCC and has been shown
to be immunogenic in murine models and human cell culture.
46
Because the frequency of GPC3-specific T cells is low in the
peripheral blood of HCC patients, optimized costimulatory
conditions may be required for ex vivo expansion of these cells.
47
NY-ESO-1 is an additional cancer/testes antigen expressed in
HCC. Spontaneous CD8+ T cell and antibody responses have
been detected in HCC patients, supporting the use of NY-ESO-1
as an immunotherapy target in HCC.
45 Wilms’ tumor 1 (WT-1)
has also been identified as a tumor-associated antigen in HCC.
48
Importantly, elevated WT-1 expression is also found in hepato-
cytes from patients with fibrosis and chronic hepatitis, two
common conditions preceding HCC development.
49 Finally,
because telomerase activity is upregulated during hepatocarcino-
genesis, telomerase-based vaccines have been tested in HCC
patients, although the initial trial results did not show evidence
of immune or clinical responses.
45,50
Current immunotherapy of HCC. Results from several clinical
trials demonstrate that immune-based therapy can improve out-
comes for patients with HCC.
51 In one large trial, 150 patients
were randomized to receive either IL-2 and anti-CD3-activated
PBMC or observation post curative resection.
52 There were
statistically significant improvements in time to recurrence as
well as recurrence-free survival (overall survival was improved,
p = 0.09). The largest trial testing infusion of APC included 31
HCC patients who received DC pulsed with autologous tumor
lysate.
53 Overall, there were 14 partial responses and 17 disease
stabilizations, and patients had an improved 1 y survival (63%
vs. 10%; p = 0.038). These results support the notion of DC-
based immunotherapy for HCC. Murine models also support
immunotherapy, most recently demonstrating that DC in com-
bination with IL-12 in an adjuvant setting activates T and NK
cells and reduces HCC recurrence.
54
Future Immunotherapeutic Strategies
New approaches. In light of the numerous regulatory mechan-
isms that HCC tumors employ to evade an immune attack, a
major goal of novel immunotherapies in HCC will be to
antagonize these regulatory circuits. The CTLA-4 blocking
antibody ipilimumab is capable of inducing durable clinical
responses and objective response rates of approximately 10% in
metastatic melanoma.
55 In the setting of HCC, ex vivo treatment
of CD8+ T cells isolated from HCC patients with CTLA-4
blocking antibodies resulted in an expanded antigen-specific T cell
repertoire, suggesting that ipilimumab likely possesses high
potential for the treatment of HCC.
56 Antibody-mediated
blockade of PD-1 has demonstrated therapeutic benefit in the
setting of refractory solid tumors, while inhibition of Tim-3
signaling in pre-clinical models has been shown to restore anti-
tumor T cell activity.
57,58 Moreover, Treg-depleting reagents, such
as denileukin diftitox (Ontak), that target the constitutively-
expressed molecule CD25, have been shown to effectively
eliminate circulating Tregs without coordinate depletion of
activated, CD25-expressing T effector cells.
59 Another strategy
to overcome tumor-mediated immunosuppression involves the
direct reactivation of hyporesponsive tumor-specific T cells
through provision of T cell growth factors (IL-15, IL-7) or
costimulatory agonists (anti-4–1BB, anti-OX40).
60,61 Although
these reagents have been tested extensively in other prevalent
cancers, their therapeutic potential in HCC has unfortunately yet
to be explored.
Treatment modalities that amplify tumor homing and penetra-
tion of T effector cells are also anticipated to have significant
therapeutic potential in HCC, given the well-established correla-
tion between T cell infiltration of HCC lesions and overall
survival.
34 These strategies can be divided into two general
categories: (1) normalization of the tumor vasculature and (2)
chemokine and adhesion molecule upregulation.
The vasculature of highly angiogenic cancers, such as HCC,
is characterized by disorganized, tortuous vessels that restrict the
infiltration of nutrients, oxygen, therapeutic drugs and tumor-
primed T cells.
62 In pre-clinical models, treatment-induced
remodeling of the tumor vasculature has restored T cell infiltra-
tion of tumors and demonstrated anti-tumor efficacy.
63 Currently
however, small molecule drugs and monoclonal antibodies target-
ing VEGF and its receptors, including sorafenib and bevacizu-
mab, have demonstrated limited therapeutic efficacy in HCC
clinical trials.
6,7 Immunotherapy targeting angiogenesis and/or the
tumor vasculature represents a feasible alternative based on the
potential to generate long-lived anti-vascular T cell responses.
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This notion is supported by pre-clinical data from Niethammer
and colleagues, who show that an anti-VEGFR2 vaccine sup-
presses angiogenesis and tumor dissemination through a T cell-
dependent process.
64 Immune-based anti-angiogenic agents may
therefore prove useful in the setting of HCC.
Circulating T cells extravasate into peripheral tissues through
recognition of adhesion molecules, including ICAM-1 and
VCAM-1, which are upregulated by vascular endothelial cells in
response to inflammatory conditions. In the healthy liver, VLA-4-
expressing Th1 cells are preferentially recruited via VCAM-1 on
the sinusoidal venules.
65 VCAM-1 also plays an important role
in the sequestration of activated T cells in the liver micro-
vasculature.
66 These data suggest that strategies to upregulate
VCAM-1 expression on the tumor vasculature will likely augment
pre-existing or therapy-induced anti-HCC T cell activity. The
importance of pro-inflammatory chemokine molecules in HCC-
specific T cell immunity has also been demonstrated, as high
levels of the IFN-c-inducible chemokines CXCL9/Mig and
CXCL10/IP-10 correlated with HCC tumor enrichment of
CD8+ T cells.
67 Although this pattern of chemokine expression
correlates with favorable prognosis of patients with uterine/
cervical cancers, it is currently unclear whether the same is true
for HCC patients.
68 Therapeutic reagents that induce chemo-
kine and adhesion molecule expression through vascular activa-
tion are therefore an attractive approach for the immune-based
treatment of HCC.
Combinational regimens. Although single agent modalities
have demonstrated some efficacy in the clinic, immunotherapy
in combination with conventional treatments (chemo-
immunotherapy) or other immunotherapies is expected to elicit
synergistic anti-tumor activity. Several chemotherapeutic agents,
including adriamycin, cisplatin and gemcitabine are commonly
used for ablative treatment of HCC. A number of recent
studies have more closely examined the immunological impact
of some of these agents in various tumor types and the modes
of death induced by them.
69 For example, gemcitabine-induced
tumor apoptosis can promote tumor antigen cross-presentation
by DC and resultant T cell responses.
70 Non-chemotherapeutic
ablative therapies for HCC, including transarterial embolization
(TAE) and radiofrequency ablation (RFA), can induce immuno-
genic tumor cell death as well. Embolized patients tested before
and following treatment increased the frequency of AFP-specific
CD4+ T cells, while HCC patients tested after RFA demon-
strated improved T cell responses to autologous tumor and had
increased circulating NK cell frequencies, likely due to the
immunogenicity of released antigen.
71,72 Early evidence suggests
that immunotherapy will be most effective during or shortly
after ablative therapy, when tumor cells are dying and an active
immune response has commenced. In HCC, combined therapy of
TAE with intratumoral dendritic cell infusion induced higher
frequencies of AFP-specific T cells compared with TAE alone.
73
Therefore, there are many opportunities for combining immu-
notherapy with an immunogenic form of HCC ablation to
improve antitumor responses. The rational choice of the ablation
approach may provide an improved and more immunogenic
setting for subsequent immunization, and potentially a “priming”
event after which a vaccine would be a “boost” in a combination
therapy.
Despite the observation that long-term IFN-a therapy in
patients with advanced hepatitis C does not reduce the incidence
of HCC, IFN-a administration in combination with tumor-
specific vaccination, which elicited synergistic anti-tumor T cell
activity in melanoma patients, could be a viable therapeutic
option in the setting of HCC.
74,75 Many opportunities clearly
exist for therapeutic intervention in advanced HCC, including
both single agent modalities and combinational regimens (Fig.2).
Optimal therapeutic strategies in HCC will presumably involve
combinations of immunotherapy that engage multiple immune
effector mechanisms, such as vaccines and T cell immunomodu-
lators, as well as immunotherapy supplemented with molecularly
targeted inhibitors of tumor signaling pathways.
76
Conclusions and Additional Considerations
As described above, the distinctly immunosuppressive milieu of
both the steady-state and diseased liver serves as a considerable
obstacle to effective HCC immunotherapy. Beyond the tolero-
genic microenvironment, however, there are additional properties
unique to HCC that may further impede the successful imple-
mentation of immunotherapy. First, many investigators have
observed extensive patient-to-patient heterogeneity in the mole-
cular and cellular makeup of HCC tumors, and accumulating
evidence suggests that this is likely a result of the multiple
etiological factors involved in hepatocarcinogenesis (i.e., HBV/
HCV infection, chronic alcohol consumption, metabolic syn-
drome).
77 For example, preferential upregulation of NK cell-
associated KIRs (killer cell immunoglobulin-like receptors) has
been reported in HCV-infected (and not HBV-infected) HCC
patients.
78 Due to the inhibitory nature of KIR molecules, HCV-
related HCC tumors may be particularly resistant to NK cell-
mediated cytotoxicity compared with HCC lesions of alternative
etiologies. Additionally, Miroux and colleagues have suggested
that because negligible frequencies of Tregs are found in alcohol-
related HCC patients, Treg recruitment to the liver may be
specifically linked to HCV infection.
17 Although more research
must be done in this area, differing etiologies likely have a
direct impact on disease course and treatment outcome, and
therapeutic regimens may need to be tailored to individual HCC
patients based on their distinct etiological factor(s). Lastly, in
the minority of HCC patients who are eligible for and receive
liver transplantation, recurrent disease develops in up to 20%
of these patients.
5 It has been hypothesized that immuno-
suppressant agents directly contribute to post-transplant HCC
recurrence by promoting tumor immune evasion.
79 The choice
of immunosuppressive drug based on their differential modes
of action could therefore prove important in the prevention of
HCC recurrence following liver transplantation.
80
While early-phase clinical trials serve as proof-of-concept that
immunotherapy of HCC is safe, feasible, and moderately effec-
tive, future trials must take into account several unique properties
of HCC that may have limited the success of previous trials.
Inclusion criteria should be tightened to reduce heterogeneity
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among patients, etiologic factors and liver function. Blood and
tissue samples need to routinely be banked in order to help
identify patient subsets and biomarkers of response (both
predictive and prognostic). Finally, therapeutic agents that are
capable of reversing the immunosuppressive nature of HCC
tumors, administered alone or more likely in combination with
other modalities, will be critical to optimizing clinical outcomes
for HCC patients.
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